GLP1 and cancer: friend or foe?
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
The new incretin-based therapies, dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon like peptide 1 (GLP1) receptor agonists are widely used for the treatment of type 2 diabetes because of their glucose-lowering capacity with low risk of hypoglycemia. As they are weight neutral or induce weight loss in this mostly overweight population, they are popular among clinicians and patients alike. Nonetheless, concerns have been raised about GLP1's trophic effects. While increased β cell mass observed in rodents sounds appealing for treatment of diabetes, there was also an increased incidence of medullary thyroid cancer (MTC) in some species. We reviewed literature available in the Medline database until March 2012. Safety signals have emerged for MTC and pancreatic carcinoma from adverse event databases in the United States and Europe. Considering the relatively short duration of these studies, it is more likely that premalignant lesions are stimulated in presence of GLP1, rather than new neoplasms induced. Moreover, interpreting results of animal studies is difficult because of species-specific differences in presence and density of GLP1 receptors. Furthermore, data are emerging suggesting beneficial effects of GLP1 on colon and breast cancer. In conclusion, presently, the benefits of using DPP4 inhibitors or GLP1 receptor agonists for treatment of type 2 diabetes outweigh the risks. Nonetheless, their safety profile should be monitored and their indications should be widened cautiously. At present they remain contra-indicated in patients with a personal or family history of MTC or multiple endocrine neoplasia type 2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distant metastasis occurs late during the genetic evolution of pancreatic cancer
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“Metformin, for example, which is frequently combined with incretin mimetics, is associated with a decreased cancer risk (Evans et al. 2005), and decreased mortality in cancer patients (Gallagher & LeRoith 2011).”
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · cited 1×
“There have been reports suggesting that both treatment with exenatide (also known as Exendin-4; Denker & Dimarco 2006, Cure et al. 2008, Tripathy et al. 2008) and liraglutide (Buse et al. 2009), the most commonly used GLP1 receptor agonists, is associated with an increased risk of pancreatitis.”
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124 · cited 1×
“In physiological circumstances, GLP1 and GIP have an extremely short half-life as they are almost immediately inactivated by the enzyme DPP4 (Kieffer et al. 1995).”
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 1×
“Sulfonylurea on the other hand, might increase risk for pancreatitis (Blomgren et al. 2002) and solid tumors (Currie et al. 2009).”
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 3×
“…treated with exenatide was clearly higher – with an odds ratio 4.7 (30 events), www.endocrinology-journals.org Downloaded from Bioscientifica.com at 12/08/2018 10:23:06PM via free access compared with sitagliptin (two events) and the panel of control drugs (three events) (Elashoff et al. 2011).”
InfluentialBjerre Knudsen, L., Madsen, L. W., Andersen, S., Almholt, K., de Boer, A. S., Drucker, D. J., Gotfredsen, C., Egerod, F. L., Hegelund, A. C., Jacobsen, H., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1272 · Cited by 672
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · cited 1×
“Moreover, these high levels are also present in the peripheral circulation (Agerso et al. 2002).”
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · cited 2×
“A few of the tested ovarian and prostate carcinoma cases seemed GLP1 receptor positive (Korner et al. 2007).”
Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421 · cited 2×
“…works by either increasing the concentration of the endogenous incretins by preventing deactivation by dipeptidyl peptidase-4 (DPP4) inhibitors (Ahren et al. 2002) or by mimicking the incretins biochemically (glucagon like peptide 1 (GLP1) receptor agonists) while being protected from DPP4…”
Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394 · cited 1×
“Finally, reduction in markers of inflammation and oxidative stress has been reported (Kodera et al. 2011).”
Kang, G., Joseph, J. W., Chepurny, O. G., Monaco, M., Wheeler, M. B., Bos, J. L., Schwede, F., Genieser, H.-G., & Holz, G. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211682200 · Cited by 298 · cited 1×
“GLP1 binds to its specific G-protein coupled receptor, which activates downstream pathways including cAMP/protein kinase A (PKA), cAMP/guanine-nucleotide exchange factor (Epac) or phosphatidylinositol-3 kinase/PKC pathways (Gromada et al. 1998, Kang et al. 2003, MacDonald et al. 2003; see Fig.”
On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane
Moore, B., Edie, E. S., & Abram, J. H. (1906) · Biochemical Journal · doi:10.1042/bj0010028 · Cited by 279 · cited 2×
“They are all based on the so-called incretin effect, known since the early 1900s (Bayliss & Starling 1902, Moore 1906; see below).”
Hegedüs, L., Moses, A. C., Zdravkovic, M., Le Thi, T., & Daniels, G. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2318 · Cited by 194 · cited 1×
“Data gained from several prospective clinical studies, showed no increased calcitonin levels under therapy with GLP1 receptor agonists in patients with diabetes mellitus type 2 (Bjerre Knudsen et al. 2010, Hegedus et al. 2011).”
Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
Nachnani, J. S., Bulchandani, D. G., Nookala, A., Herndon, B., Molteni, A., Pandya, P., Taylor, R., Quinn, T., Weide, L., & Alba, L. M. (2010) · Diabetologia · doi:10.1007/s00125-009-1515-4 · Cited by 189 · cited 1×
“Exenatide, the most studied GLP1 receptor agonist, has also been shown to promote pancreatic duct hyperplasia in rats (Nachnani et al. 2010).”
Madsen, L. W., Knauf, J. A., Gotfredsen, C., Pilling, A., Sjögren, I., Andersen, S., Andersen, L., Sietske de Boer, A., Manova, K., Barlas, A., et al. (2012) · Endocrinology · doi:10.1210/en.2011-1864 · Cited by 161 · cited 1×
“Recently, the group of Madsen et al. (2012) reported that liraglutide binding to the GLP1 receptor on C cells leading tot C-cell hyperplasia in wild type mice does not lead to RET kinase activation, but rather mTOR activation, which is reassuring to a certain extent as activation of this RET…”
Glucagon Like Peptide-1 Receptor Expression in the Human Thyroid Gland
Gier, B., Butler, P. C., Lai, C. K., Kirakossian, D., DeNicola, M. M., & Yeh, M. W. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2407 · Cited by 157
Exenatide (Exendin-4)–Induced Pancreatitis
Denker, P. S., & Dimarco, P. E. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-2043 · Cited by 140 · cited 1×
“There have been reports suggesting that both treatment with exenatide (also known as Exendin-4; Denker & Dimarco 2006, Cure et al. 2008, Tripathy et al. 2008) and liraglutide (Buse et al. 2009), the most commonly used GLP1 receptor agonists, is associated with an increased risk of pancreatitis.”
The Human GLP-1 Analog Liraglutide and the Pancreas
Nyborg, N. C. B., Mølck, A.-M., Madsen, L. W., & Bjerre Knudsen, L. (2012) · Diabetes · doi:10.2337/db11-0936 · Cited by 125 · cited 2×
“The conclusion of the authors is that although these data are derived from nondiabetic animals, simple pharmacological induction of pancreatitis by GLP1 receptor agonists seems unlikely (Nyborg et al. 2012).”
Waser, B., Beetschen, K., Pellegata, N. S., & Reubi, J. C. (2011) · Neuroendocrinology · doi:10.1159/000330447 · Cited by 80
Research works printed but not linked: 49
- 2004, BEST PRACTICE RESEARCH CLINICAL ENDOCRINOLOGY METABOLISM, 18, 531, 10.1016/j.beem.2004.08.001 · DOI
- 2009, JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 3, 245, 10.1016/j.jash.2009.04.001 · DOI
- Bayliss, 1902, The Journal of Physiology, 28, 325, 10.1113/jphysiol.1902.sp000920 · DOI · Paper page
- Blomgren, 2002, Diabetes Care, 25, 298, 10.2337/diacare.25.2.298 · DOI · Paper page
- 2004, Endocrinology, 145, 2653, 10.1210/en.2004-0015 · DOI · Paper page
- Bullock, 1996, Endocrinology, 137, 2968, 10.1210/en.137.7.2968 · doi:10.1210/en.137.7.2968 · Paper page
- Butler, 2010, 53, 21, 10.1007/s00125-009-1556-8 · DOI · Paper page
- Cure, 2008, New England Journal of Medicine, 358, 1969, 10.1056/NEJMc0707137 · DOI · Paper page
- 2011, DIABETES OBESITY METABOLISM, 13, 559, 10.1111/j.1463-1326.2011.01376.x · DOI · Paper page
- Drucker, 2011, Lancet, 377, 977, 10.1016/S0140-6736(10)62299-4 · DOI
- Drucker, 1986, Journal of Biological Chemistry, 261, 9637, 10.1016/S0021-9258(18)67561-1 · DOI · Paper page
- Drucker, 1996, PNAS, 93, 7911, 10.1073/pnas.93.15.7911 · DOI · Paper page
- Fehmann, 1992, Endocrinology, 130, 159, 10.1210/en.130.1.159 · DOI · Paper page
- Fineman, 2003, Diabetes Care, 26, 2370, 10.2337/diacare.26.8.2370 · DOI · Paper page
- Gallagher, 2011, Annals of the New York Academy of Sciences, 1243, 54, 10.1111/j.1749-6632.2011.06285.x · DOI · Paper page
- 2010, Diabetes Care, 33, 2349, 10.2337/dc10-0482 · DOI · Paper page
- Ghatei, 2001, Digestive diseases and sciences, 46, 1255, 10.1023/A:1010615429639 · DOI
- 1984, 27, 599, 10.1007/BF00276976 · DOI
- 2010, DIABETES OBESITY METABOLISM, 12, 766, 10.1111/j.1463-1326.2010.01231.x · DOI · Paper page
- Gromada, 1998, Diabetes, 47, 57, 10.2337/diab.47.1.57 · DOI · Paper page
- Hartmann, 2000, Endocrinology, 141, 4013, 10.1210/en.141.11.4013 · doi:10.1210/en.141.11.4013
- Havre, 2008, Frontiers in bioscience : a journal and virtual library, 13, 1634, 10.2741/2787 · DOI · Paper page
- Hjollund, 2011, 54, 2206, 10.1007/s00125-011-2168-7 · DOI
- 1997, American Journal of Physiology -- Legacy Content, 273, G920
- Jura, 2005, Cell research, 15, 72, 10.1038/sj.cr.7290269 · DOI
- Kieffer, 1995, Endocrinology, 136, 3585, 10.1210/en.136.8.3585 · DOI · Paper page
- Koehler, 2006, Diabetes, 55, 1369, 10.2337/diabetes. · doi:10.2337/diabetes · Paper page
- Koehler, 2008, Cancer Research, 68, 7897, 10.1158/0008-5472.CAN-08-0029 · DOI
- 2011, Endocrinology, 152, 3362, 10.1210/en.2011-1201 · DOI · Paper page
- Kreymann, 1987, Lancet, 2, 1300, 10.1016/S0140-6736(87)91194-9 · DOI · Paper page
- Ligumsky, 2012, Breast cancer research and treatment, 132, 449, 10.1007/s10549-011-1585-0 · DOI
- Livolsi, 1979, American Journal of Clinical Pathology, 71, 595, 10.1093/ajcp/71.5.595 · DOI
- 2003, Journal of Biological Chemistry, 278, 52446, 10.1074/jbc.M307612200 · DOI · Paper page
- Masur, 2006, Regulatory peptides, 137, 147, 10.1016/j.regpep.2006.07.003 · DOI
- Matteucci, 2009, Current medicinal chemistry, 16, 2943, 10.2174/092986709788803114 · DOI · Paper page
- 2009, Diabetes, 58, 1604, 10.2337/db09-0058 · DOI · Paper page
- Munroe, 1999, PNAS, 96, 1569, 10.1073/pnas.96.4.1569 · DOI · Paper page
- NAUCK, 1989, Journal of Clinical Endocrinology & Metabolism, 69, 654, 10.1210/jcem-69-3-654 · DOI · Paper page
- 2010, New England Journal of Medicine, 362, 774, 10.1056/NEJMp1001578 · DOI · Paper page
- 2009, Gut, 58, 97, 10.1136/gut.2008.149179 · DOI · Paper page
- 2006, 107, 2134, 10.1002/cncr.22244 · DOI · Paper page
- 1983, 85, 1120
- Stoffers, 2000, Diabetes, 49, 741, 10.2337/diabetes.49.5.741 · DOI · Paper page
- Thulesen, 2004, Gut, 53, 1145, 10.1136/gut.2003.035212 · DOI · Paper page
- Tran, 1996, Cancer Epidemiology Biomarkers & Prevention, 5, 1013
- Tripathy, 2008, The Journal of the Association of Physicians of India, 56, 987
- Vilsboll, 2001, Diabetes, 50, 609, 10.2337/diabetes.50.3.609 · DOI · Paper page
- Xia, 1995, Science, 270, 1326, 10.1126/science.270.5240.1326 · DOI · Paper page
- Xu, 1999, Diabetes, 48, 2270, 10.2337/diabetes.48.12.2270 · DOI · Paper page
Cited by
The global implications of diabetes and cancer
Shi, Y., & Hu, F. B. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60886-2 · Cited by 424
G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus
Riddy, D. M., Delerive, P., Summers, R. J., Sexton, P. M., & Langmead, C. J. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014373 · Cited by 108
“Activation of membrane-bound G protein– coupled receptors (GPCRs) enhances insulin secretion via PKC activation or through an increase in cAMP, which activates protein kinase A and potentiates the Ca2+ influx (Heit et al., 2006; Vangoitsenhoven et al., 2012).”
Zhao, H., Wang, L., Wei, R., Xiu, D., Tao, M., Ke, J., Liu, Y., Yang, J., & Hong, T. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12291 · Cited by 88
Wang, J., & Kim, C. H. (2022) · Endocrine Research · doi:10.1080/07435800.2021.1955255 · Cited by 74
An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers
Tseng, C.-H., Lee, K.-Y., & Tseng, F.-H. (2015) · Journal of Environmental Science and Health, Part C · doi:10.1080/10590501.2015.1003496 · Cited by 49
“Thyroid Cancer The presence of GLP-1R on thyroid tissues varies among different species [162].”
Background
Metadata
- Authors
- Vangoitsenhoven, R., Mathieu, C., & Van der Schueren, B.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2012-06-12
- Volume
- 19
- Issue
- 5
- Pages
- F77-F88
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2136840982
- Cited by
- 73
- References
- 21
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.